GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » Piotroski F-Score

ISCO (International Stem Cell) Piotroski F-Score : 4 (As of Mar. 18, 2025)


View and export this data going back to 2006. Start your Free Trial

What is International Stem Cell Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

International Stem Cell has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for International Stem Cell's Piotroski F-Score or its related term are showing as below:

ISCO' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of International Stem Cell was 8. The lowest was 2. And the median was 4.


International Stem Cell Piotroski F-Score Historical Data

The historical data trend for International Stem Cell's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

International Stem Cell Piotroski F-Score Chart

International Stem Cell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 4.00 3.00 8.00 6.00

International Stem Cell Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 6.00 6.00 5.00 4.00

Competitive Comparison of International Stem Cell's Piotroski F-Score

For the Biotechnology subindustry, International Stem Cell's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


International Stem Cell's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where International Stem Cell's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was -0.458 + -0.214 + 0.119 + -0.125 = $-0.68 Mil.
Cash Flow from Operations was 0.161 + -0.193 + 0.023 + 0.257 = $0.25 Mil.
Revenue was 1.889 + 2.129 + 2.331 + 2.179 = $8.53 Mil.
Gross Profit was 1.026 + 1.242 + 1.418 + 1.205 = $4.89 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(5.641 + 5.39 + 5.369 + 5.594 + 5.18) / 5 = $5.4348 Mil.
Total Assets at the begining of this year (Sep23) was $5.64 Mil.
Long-Term Debt & Capital Lease Obligation was $0.20 Mil.
Total Current Assets was $3.49 Mil.
Total Current Liabilities was $4.72 Mil.
Net Income was 0.023 + -0.034 + 0.492 + -0.131 = $0.35 Mil.

Revenue was 2.43 + 2.086 + 1.841 + 1.973 = $8.33 Mil.
Gross Profit was 1.294 + 1.262 + 1.128 + 1.192 = $4.88 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(5.042 + 5.135 + 5.341 + 5.786 + 5.641) / 5 = $5.389 Mil.
Total Assets at the begining of last year (Sep22) was $5.04 Mil.
Long-Term Debt & Capital Lease Obligation was $0.52 Mil.
Total Current Assets was $3.66 Mil.
Total Current Liabilities was $4.68 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

International Stem Cell's current Net Income (TTM) was -0.68. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

International Stem Cell's current Cash Flow from Operations (TTM) was 0.25. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=-0.678/5.641
=-0.12019146

ROA (Last Year)=Net Income/Total Assets (Sep22)
=0.35/5.042
=0.0694169

International Stem Cell's return on assets of this year was -0.12019146. International Stem Cell's return on assets of last year was 0.0694169. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

International Stem Cell's current Net Income (TTM) was -0.68. International Stem Cell's current Cash Flow from Operations (TTM) was 0.25. ==> 0.25 > -0.68 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=0.203/5.4348
=0.03735188

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=0.518/5.389
=0.09612173

International Stem Cell's gearing of this year was 0.03735188. International Stem Cell's gearing of last year was 0.09612173. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=3.49/4.718
=0.73972022

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=3.658/4.682
=0.78129005

International Stem Cell's current ratio of this year was 0.73972022. International Stem Cell's current ratio of last year was 0.78129005. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

International Stem Cell's number of shares in issue this year was 8.004. International Stem Cell's number of shares in issue last year was 8.004. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4.891/8.528
=0.57352251

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4.876/8.33
=0.58535414

International Stem Cell's gross margin of this year was 0.57352251. International Stem Cell's gross margin of last year was 0.58535414. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=8.528/5.641
=1.51178869

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=8.33/5.042
=1.65212217

International Stem Cell's asset turnover of this year was 1.51178869. International Stem Cell's asset turnover of last year was 1.65212217. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

International Stem Cell has an F-score of 4 indicating the company's financial situation is typical for a stable company.

International Stem Cell  (OTCPK:ISCO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


International Stem Cell Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of International Stem Cell's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


International Stem Cell Business Description

Traded in Other Exchanges
N/A
Address
9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
Executives
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Andrei Semechkin 10 percent owner 1 OVERLOOK DR. UNIT 11, AMHERST NH 03031
Sofya Bakalova officer: Dir. of Legal Affairs & Oper. 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Wright Don director 2829 RUCKER AVE, 3RD FLOOR, EVERETT WA 98201
Jennifer Stephens officer: Acting Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Mahnaz Ebrahimi officer: Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Rouslan Semechkin director, 10 percent owner 2595 JASON CT, OCEANSIDE CA 92056
Tibor Jay Novak officer: Interim CFO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
John Simon Craw officer: Executive Vice President 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
James H Berglund director C/O INTERNATIONAL STEM CELL CORPORATION, 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Ar Partners Llc 10 percent owner 5950 PRIESTLY DR., CARLSBAD CA 92008
Kurt Andrew May officer: President and COO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Linh T Nguyen officer: Chief Financial Officer 5950 PRIESTLY DR., CARLSBAD CA 92008
Jeffrey Janus director, officer: President 2595 JASON COURT, OCEANSIDE CA 92056
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027